ECI appoints Raja to senior advisory role

ECI appoints Raja to senior advisory role

ECI has appointed Khalid Raja to strengthen senior regulatory capability. The move adds leadership experience across quality, compliance, manufacturing, and commercialisation.


Enhanced Compliance Inc. (ECI) has appointed Khalid Raja as Senior Vice President, Strategic Growth & Advisory, strengthening its senior bench in regulatory, quality, and operational strategy for life sciences manufacturers.

Raja brings more than 30 years of experience across quality, regulatory affairs, manufacturing, supply chain, and global operations in the medical device and life sciences sector. He most recently served as Global Vice President of Quality & Compliance for Robotics and Digital Surgery at Johnson & Johnson.

Before that, he held senior leadership roles at Dentsply Sirona, Philips, Bausch & Lomb, and Boston Scientific, where his responsibilities covered quality systems, regulatory approvals, remediation programmes, and operational transformation across complex international organisations.

Brijesh Patel, Chief Executive Officer of ECI, said: “His background leading large-scale quality and compliance functions across some of the most respected companies in our industry will be instrumental as we continue to expand our capabilities and support clients through increasingly complex product and regulatory landscapes.”

ECI said Raja will work closely with clients on regulatory and quality strategy, support complex engagements, and drive growth across strategic accounts and key markets. The company’s model combines quality and regulatory expertise with engineering execution, packaging, and laboratory testing, giving it a broader role across the product lifecycle than a pure advisory business.

Raja said: “ECI’s model — combining quality, regulatory, and engineering expertise with testing lab and commercialization readiness — positions it uniquely to support clients across the full product lifecycle.”

The appointment adds senior experience at a point when life sciences manufacturers are managing tighter quality requirements, more demanding documentation expectations, and growing pressure to move products through development, validation, and market entry without regulatory delay.


Stories for you